U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Grade 1 Other Gastrointestinal, CTCAE

MedGen UID:
294705
•Concept ID:
C1560442
•
Finding
Synonym: CTCAE Grade 1 Gastrointestinal - Other

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVGrade 1 Other Gastrointestinal, CTCAE

Professional guidelines

PubMed

Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Morales-Barrera R, Villacampa G, Vidal N, Figols M, Giner J, Bonfill T, Suárez C, Díaz N, Mateo J, González M, Domenech M, Puente J, Carles J
Clin Transl Oncol 2023 Dec;25(12):3556-3564. Epub 2023 May 22 doi: 10.1007/s12094-023-03213-6. PMID: 37217634
Highly conformal combined radiotherapy with cisplatin and gemcitabine for treatment of loco-regionally advanced cervical cancer - a retrospective study.
Cihoric N, Tsikkinis A, Vlaskou Badra E, Glatzer M, Novak U, Scherz A, Shelan M, Soldatovic I, Yojena CKK, Aebersold DM, Lössl K
Radiat Oncol 2017 Dec 22;12(1):202. doi: 10.1186/s13014-017-0938-1. PMID: 29273076Free PMC Article
Management of sorafenib-related adverse events: a clinician's perspective.
Brose MS, Frenette CT, Keefe SM, Stein SM
Semin Oncol 2014 Feb;41 Suppl 2:S1-S16. Epub 2014 Jan 9 doi: 10.1053/j.seminoncol.2014.01.001. PMID: 24576654

Recent clinical studies

Etiology

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X, Xiao YT, Yang Y, Ye Y, Chang Y, Jiang L, Eftekhar M, Ren S, Zhang H
Cancer Control 2022 Jan-Dec;29:10732748221120462. doi: 10.1177/10732748221120462. PMID: 35980734Free PMC Article
Outcomes of Squamous Cell Carcinoma Anal Canal treated with IMRT-VMAT-based Concurrent Chemoradiation: a Single Institutional Experience.
Singh K, Sathyamurthy A, Ramireddy JK, Ram TS
J Gastrointest Cancer 2022 Mar;53(1):161-169. Epub 2021 Jan 5 doi: 10.1007/s12029-020-00580-z. PMID: 33400211
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA
Clin Oncol (R Coll Radiol) 2018 Jul;30(7):418-426. Epub 2018 Mar 28 doi: 10.1016/j.clon.2018.02.067. PMID: 29602584
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F
Anticancer Drugs 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492. PMID: 28296649

Diagnosis

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I
Cancer Chemother Pharmacol 2020 Nov;86(5):607-618. Epub 2020 Sep 23 doi: 10.1007/s00280-020-04135-8. PMID: 32965539Free PMC Article
Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL, Yip TC, Wong VW, Tse YK, Yuen BW, Luk HW, Lui RN, Chan HL, Mok TS, Wong GL
Cancer Med 2020 Oct;9(19):7052-7061. Epub 2020 Aug 11 doi: 10.1002/cam4.3378. PMID: 32780516Free PMC Article
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Shin SK, Kim DY
Int J Radiat Oncol Biol Phys 2011 Dec 1;81(5):1343-51. Epub 2010 Oct 8 doi: 10.1016/j.ijrobp.2010.07.1986. PMID: 20934268
Fasting and cancer treatment in humans: A case series report.
Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD
Aging (Albany NY) 2009 Dec 31;1(12):988-1007. doi: 10.18632/aging.100114. PMID: 20157582Free PMC Article

Therapy

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML
JAMA Oncol 2023 Mar 1;9(3):365-373. doi: 10.1001/jamaoncol.2022.6558. PMID: 36633877Free PMC Article
Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer.
Rajan A, Gray JE, Devarakonda S, Birhiray R, Korchin B, Menius E, Donahue RN, Schlom J, Gulley JL
Int J Cancer 2023 Feb 1;152(3):447-457. Epub 2022 Sep 9 doi: 10.1002/ijc.34267. PMID: 36054490Free PMC Article
Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
Zhao X, Xiao YT, Yang Y, Ye Y, Chang Y, Jiang L, Eftekhar M, Ren S, Zhang H
Cancer Control 2022 Jan-Dec;29:10732748221120462. doi: 10.1177/10732748221120462. PMID: 35980734Free PMC Article
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I
Cancer Chemother Pharmacol 2020 Nov;86(5):607-618. Epub 2020 Sep 23 doi: 10.1007/s00280-020-04135-8. PMID: 32965539Free PMC Article

Prognosis

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli G
Eur J Nucl Med Mol Imaging 2021 Sep;48(10):3260-3267. Epub 2021 Feb 18 doi: 10.1007/s00259-021-05236-z. PMID: 33604690Free PMC Article
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I
Cancer Chemother Pharmacol 2020 Nov;86(5):607-618. Epub 2020 Sep 23 doi: 10.1007/s00280-020-04135-8. PMID: 32965539Free PMC Article
Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Holyoake DLP, Warren DR, Hurt C, Aznar M, Partridge M, Mukherjee S, Hawkins MA
Clin Oncol (R Coll Radiol) 2018 Jul;30(7):418-426. Epub 2018 Mar 28 doi: 10.1016/j.clon.2018.02.067. PMID: 29602584
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F
Anticancer Drugs 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492. PMID: 28296649

Clinical prediction guides

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi MP, Amoroso V, Giuffrida D, Panzuto F, Campana D, Prinzi N, Milione M, Cascella T, Spreafico C, Randon G, Oldani S, Leporati R, Scotto G, Pulice I, Stocchetti BL, Porcu L, Coppa J, Di Bartolomeo M, de Braud F, Pusceddu S
BMC Cancer 2023 Sep 26;23(1):908. doi: 10.1186/s12885-023-11287-2. PMID: 37752423Free PMC Article
Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA, Sheng K, Sharma S, Nickols NG, Pham J, Yang Y, Gao Y, Neylon J, Basehart V, Cao M, Steinberg ML
JAMA Oncol 2023 Mar 1;9(3):365-373. doi: 10.1001/jamaoncol.2022.6558. PMID: 36633877Free PMC Article
Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer.
Rajan A, Gray JE, Devarakonda S, Birhiray R, Korchin B, Menius E, Donahue RN, Schlom J, Gulley JL
Int J Cancer 2023 Feb 1;152(3):447-457. Epub 2022 Sep 9 doi: 10.1002/ijc.34267. PMID: 36054490Free PMC Article
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M, Saito Y, Kato T, Satake H, Makiyama A, Tsuji Y, Shinozaki K, Fujiwara T, Mizushima T, Harihara Y, Nagata N, Kurihara N, Ando M, Kusakawa G, Sakai T, Uchida Y, Takamoto M, Kimoto S, Hyodo I
Cancer Chemother Pharmacol 2020 Nov;86(5):607-618. Epub 2020 Sep 23 doi: 10.1007/s00280-020-04135-8. PMID: 32965539Free PMC Article
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F
Anticancer Drugs 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492. PMID: 28296649

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...